77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, L2
Annual Report to Security Holders
Announces up to $100 Million Share Repurchase Plan
Financial Results, Press Release
News
Reports Third Quarter 2025 Financial Results and Business Highlights
Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
FY 2024
Q3
Q2
Q1
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement